Today, we will study why Cue Biopharma (CUE) is an attractive pick in 2020.
Company overview
Incorporated in 2014 and headquartered in Cambridge, Massachusetts, Cue Biopharma (CUE) is a clinical-stage biopharmaceutical company focused on developing injectable biologics targeting cancer and autoimmune diseases. The company is deploying the science of selectively engaging and modulating targeted T-cells within the body through its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells). The company is not opting for ex vivo manipulation of T-cells. Cue Biopharma’s investigational immune-oncology assets include CUE-101 currently being evaluated